BRIEF-Boehringer Ingelheim Licenses Preclinical Antibody Program From Immunitas Therapeutics To Advance Treatments For Chronic Inflammatory Diseases

May 12 (Reuters) -

  • BOEHRINGER INGELHEIM LICENSES PRECLINICAL ANTIBODY PROGRAM FROM IMMUNITAS THERAPEUTICS TO ADVANCE TREATMENTS FOR CHRONIC INFLAMMATORY DISEASES

  • BOEHRINGER INGELHEIM: UNDER AGREEMENT, TO OBTAIN WORLDWIDE RIGHTS TO DEVELOP, MANUFACTURE AND COMMERCIALIZE ANTIBODY PROGRAM

  • BOEHRINGER INGELHEIM: UNDER AGREEMENT IMMUNITAS THERAPEUTICS WILL RECEIVE UP TO EUR 407.5 MILLION, IN ADDITION TO TIERED ROYALTIES ON FUTURE SALES

Source text: ID:nGNX7v40ZX


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.